Join a Study

Scientists at the medical school are conducting hundreds of clinical trials daily. Browse our list of actively recruiting clinical trials below to learn more and find out how you may be able to participate. 

For more information about the research or participation, please call our research office at 312-503-0755 or email us at pdclinicaltrials@northwestern.edu. Learn more about all the medical school's trials via the Feinberg Research Clinical Trials section, including Volunteer FAQ

Trials
This is a registry aimed to collect biologic and clinical information, such as blood and tissue samples, and family and medical histories from patients diagnosed with a movement disorder. The purpose of studying materials from the registry is to identify factors that either cause these neurologic co…
This is a registry aimed to collect biologic and clinical information, such as blood and tissue samples, and family and medical histories from patients diagnosed with a movement disorder. The purpose of studying materials from the registry is to identify factors that either cause these neurologic conditions or increase one’s risk for developing them. Samples collected for this biorepository include a blood sample (or a saliva sample) and a skin biopsy. Participants may choose to donate one or both samples.

• Diagnosis of a movement disorder • Male or female 18 years of age or older when diagnosed • Ability to provide informed consent

Akhtar, Rizwan SmeerAkhtar, Rizwan Smeer
  • Map it 259 E. Erie St. Lavin Pavillion, Suite 19 100
    Chicago, IL
STU00091585
More Info
Copy
The purpose of this research study is to collect clinical information about patients and their health. We will also collect biological samples, such as blood and DNA (the genetic material in your blood). Researchers will use this information and samples to learn more about HD and to try to find new …
The purpose of this research study is to collect clinical information about patients and their health. We will also collect biological samples, such as blood and DNA (the genetic material in your blood). Researchers will use this information and samples to learn more about HD and to try to find new treatments for the disease. People from many countries contribute to Enroll-HD.
Individuals 18 yrs or older affected by Huntington's Disease (HD) or from a HD family or are a "community control" (a person who does not carry the HD genetic mutation that causes Huntington's disease and is not part of an HD family, but would like to participate in the study). Research visits are conducted yearly and will consists of a collection of medical and family history and biological samples.
Bega, DannyBega, Danny
  • Map it 675 N. St. Clair St. Suite 20 100
    Chicago, IL
STU00203021
More Info
Copy
The purpose of this study is to collect natural history data among ataxia patients in a cohort of SCA 1, 2, 3, 6 patients using clinic-based neurological rating scales and performance measures. Another study goal is to identify new measures of ataxia, cognition, and neurobehavior in comparison to tr…
The purpose of this study is to collect natural history data among ataxia patients in a cohort of SCA 1, 2, 3, 6 patients using clinic-based neurological rating scales and performance measures. Another study goal is to identify new measures of ataxia, cognition, and neurobehavior in comparison to traditional clinician rating methods. The gene analysis is expected to establish a relationship, if any, between age at onset of disease and disease progression rates.
• Age 18 and older
• Presence of symptoms and signs of ataxia
• Molecular diagnosis of SCA 1, 2, 3, 6 either in the participant or an affected family member
• Willingness to participate in the study and ability to give informed consent.
Opal, PuneetOpal, Puneet
  • Map it 259 E. Erie St. Lavin Pavillion, Suite 19 100
    Chicago, IL
NCT01060371 STU00204294
More Info
Copy
Subjects must be 18-65 years of age with symptoms of ataxia or a diagnosis of SCA1 or SCA3 or have an affected family member. Subjects with a previous diagnosis of early stage SCA1 or SCA 3 may also be eligible. Subject must be able to undergo a MRI (brain scan) and not weigh over 300 lbs.
Subjects aged 18 to 65 with presence of symptomatic ataxic disease or asymptomatic mutation carrier or subjects with definite molecular diagnosis of SCA1 or SCA3 or another affected family member or Subjects of age >18 with previous diagnosis of early stage SCA1 and SCA3. Subjects must not make changes in physical/occupational therapy status within two months prior to enrollment. Subjects must not weigh over 300 lbs.
5) 6) No changes in sical/occupational therapy status within two months prior to enrolment
Opal, PuneetOpal, Puneet
  • Map it 259 E. Erie St. Lavin Pavillion, Suite 19 100
    Chicago, IL
NCT03487367 STU00206988
More Info
Copy
The purpose of study is to determine whether BIIB094 may improve PD symptoms in subjects with or without changes in the LRRK2 gene. The study medication will be given as an injection into your back near the spinal cord. This iscalled an “intrathecal” injection.

2. Diagnosis of PD w/in 7yrs without motor fluctuationsor dyskinesia.

3. Not on any medication for PD or on stable therapy for 8weeks prior to screening.

Larson, Danielle NicoleLarson, Danielle Nicole
  • Map it 259 E. Erie St. Lavin Pavillion, Suite 19 100
    Chicago, IL
NCT03976349 STU00210196
More Info
Copy

This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the MDS-UPDRS Part III score at 12 months. Subjects will be randomly assigned to 2 endurance exercise groups: 1) moderate intensity exercise: 60-65% HRmax or 2) high intensity exe…

This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the MDS-UPDRS Part III score at 12 months. Subjects will be randomly assigned to 2 endurance exercise groups: 1) moderate intensity exercise: 60-65% HRmax or 2) high intensity exercise: 80-85% HRmax. The endurance exercise will be 4 days per week for approximately 30 minutes per session for 18 months.

-Diagnosis of Parkinson's disease for less than 3 years

-Cannot be treated with any PD medication

Poon, CynthiaPoon, Cynthia
NCT04284436 STU00211903
More Info
Copy
PR001A is an investigational gene therapy product that is being developed for the treatment of PD in patients with GBA1 mutations. The purpose of this study is to find out what effects PR001A has on Parkinson’s disease patients. Participants will be assigned to receive one dose of PR001A by inject…
PR001A is an investigational gene therapy product that is being developed for the treatment of PD in patients with GBA1 mutations. The purpose of this study is to find out what effects PR001A has on Parkinson’s disease patients. Participants will be assigned to receive one dose of PR001A by injection into the cisterna magna (a large space at the base of the brain).

1. 40-75 years of age.

2. Diagnosis of PD with H&Y 3-4.

3. On stable PD therapy for 8 weeks prior to baseline.

4. At least 1 GBA gene mutation.

Larson, Danielle NicoleLarson, Danielle Nicole
  • Map it 259 E. Erie St. Lavin Pavillion, Suite 19 100
    Chicago, IL
NCT04127578 STU00209947
More Info
Copy
The purpose of this study is to obtaininformation from people with and without Parkinson disease (PD) so thatresearchers may better understand how Parkinson disease progresses, in order toinform better treatments. Participants will have a neurological examination, a brain scan, provide blood samples…
The purpose of this study is to obtaininformation from people with and without Parkinson disease (PD) so thatresearchers may better understand how Parkinson disease progresses, in order toinform better treatments. Participants will have a neurological examination, a brain scan, provide blood samples and complete some questionnaires.
Simuni, TatyanaSimuni, Tatyana
  • Map it 259 E. Erie St. Lavin Pavillion, Suite 19 100
    Chicago, IL
STU00212785
More Info
Copy
The purpose of this study is to evaluate the safety and effectiveness of the study drug, pridopidine,on everyday functioning and daily activities, as well as movement and behaviorin participants with early stage Huntington Disease (HD)

1. >25yrs of age.

2. Diagnosis of HD with CAG repeat > 36

Bega, DannyBega, Danny
  • Map it 259 E. Erie St. Lavin Pavillion, Suite 19 100
    Chicago, IL
NCT04556656 STU00213780
More Info
Copy

This study is for people with early-stage Parkinson's disease. The objective of this study is to find out whether UCB0599, an investigational medication, can slow down the progression of PD. This study also tests whether UCB0599 is safe and tolerable. This study is placebo-controlled and will …

This study is for people with early-stage Parkinson's disease. The objective of this study is to find out whether UCB0599, an investigational medication, can slow down the progression of PD. This study also tests whether UCB0599 is safe and tolerable. This study is placebo-controlled and will last about 21 months. If you join the study, you will have regular scheduled appointments with the study staff and will have medical procedures and tests during these visits, like imaging studies, body function tests, and questionnaires.

You might be a candidate for this study if:

  • You are 40 - 75 years old
  • You have been diagnosed with Parkinson disease within the last two years
  • You have only mild symptoms of PD, like slowness of movement, muscle stiffness / rigidity, or tremor / shaking

There are additional eligibility criteria that will be discussed with you.

Akhtar, Rizwan SmeerAkhtar, Rizwan Smeer
  • Map it 259 E. Erie St. Nineteenth Floor
    Chicago, IL
NCT04658186 STU00214389
More Info
Copy

The purpose of this research study is to assess if an investigational product (study drug), called UX701, is an effective and safe treatment for adults aged 18 years or older with Wilson disease.

1.Individuals ≥ 18 years of age at the time of informed consent.

2. Confirmed diagnosis of Wilson disease.

3. Stable Wilson Disease with no medication or dose changes for at least 6 months at Screening.

4. Ongoing restriction of high copper containing foods for at least 6 months at Screening and continued through study participation.

Bega, DannyBega, Danny
NCT04531189 STU00214772
More Info
Copy

This study is for people who have Parkinson's disease (PD), multiple system atrophy (MSA), or progressive supranuclear palsy (PSP). The objective of this study is to find out whether an advanced imaging study can distinguish people with PD, MSA, or PSP from one another. The imaging study uses a b…

This study is for people who have Parkinson's disease (PD), multiple system atrophy (MSA), or progressive supranuclear palsy (PSP). The objective of this study is to find out whether an advanced imaging study can distinguish people with PD, MSA, or PSP from one another. The imaging study uses a brain MRI (without dye or contrast) along with a web-based automated software tool that analyzes the MRI data automatically. The study requires two visits, one at the start and one 12-18 months later. The MRI is only performed at the first visit. At each visit, there are assessments of movement and thinking, along with several questionnaires.

  • Age of 40 - 80 years
  • Ability to have a brain MRI scan
  • Clinical diagnosis of Parkinson disease at least 5 years ago, or
  • Clinical diagnosis of multiple systems atrophy (parkinsonian type), or
  • Clinical diagnosis of progressive supranuclear palsy
Akhtar, Rizwan SmeerAkhtar, Rizwan Smeer
  • Map it 259 E. Erie St. Nineteenth Floor
    Chicago, IL
STU00214779
More Info
Copy
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.

• Diagnosis of PD for at least 6 months to maximum 3 years at screening and between 50-85 years of age

• On symptomatic PD medication for at least 6 months, with a stable dose for 3 months prior to baseline

• No dyskinesisa or motor fluctuations (i.e. MDS-UPDRS Part IV = 0)

Larson, Danielle NicoleLarson, Danielle Nicole
NCT04777331 STU00214429
More Info
Copy

The purpose of this study is to evaluate the efficacy of JZP385 to improve functional and performance-based impairment due to tremor when administered once daily for up to 12 weeks

  • Participants who are diagnosed with ET
  • Participants have moderate to severe disability associated with tremor
  • Shetty, Neil KantaShetty, Neil Kanta
    NCT05122650 STU00215640
    More Info
    Copy

    The purpose of this study is to determine whether smartphone app-based digital speech assessments can provide speech data that is of

    sufficient quality and compliance to support analysis and are usable and relevant to PD and prodromal PD patients with varying ranges of speech symptom severi…

    The purpose of this study is to determine whether smartphone app-based digital speech assessments can provide speech data that is of

    sufficient quality and compliance to support analysis and are usable and relevant to PD and prodromal PD patients with varying ranges of speech symptom severity.

  • Diagnosed with PD, or
  • Prodromal PD, or
  • Age-matched healthy control
  • Simuni, TatyanaSimuni, Tatyana
    STU00216902
    More Info
    Copy

    The primary objective of the study is to assess the impact of the frequency of assessments on the variability over time, reliability, and compliance for the PD diary in patients with PD in whom medications do not provide adequate control of symptoms.

    1.≥39 to ≤70 years of age at signing of informed consent

    2. Diagnosis of clinically established PD

    3. Marked levodopa responsiveness at screening per investigator’s judgment

    4. A minimum of 3 years and a maximum of 18 years from time of PD diagnosis to the date of screening

    5. Receiving optimized and stable PD medical therapy for ≥1 month prior to screening or demonstrated intolerance to PD medications per investigator’s judgment in agreement with the medical monitor

    6. ≥3 hours of average daily OFF-time assessed within 3 months of screening by PD diary or per investigator’s judgment

    Shetty, Neil KantaShetty, Neil Kanta
    • Map it 259 E. Erie St. Lavin Pavillion, Suite 19 100
      Chicago, IL
    STU00217962
    More Info
    Copy

    The purpose of this study is to evaluate the safety of tominersen compared with placebo. The study drug will be administered via intrathecal injection.

  • HD gene expansion mutation carrier status.
  • Either Prodromal HD or Early manifest HD.
  • Total body weight > 40 kg and a body mass index within the range of 18-32 kg/m2
  • Bega, DannyBega, Danny
    NCT05686551 STU00218483
    More Info
    Copy

    The purpose of this study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).

    - The subject is ≥35 and ≤80 years of age at the time of informed consent.

    - The subject has a clinical diagnosis of PD for at least 1 year and for no longer than

    7 years before initiation of screening

    - The subject has a modified Hoehn and Yahr score ≤2.5.

    - The subject is receiving symptomatic treatment for PD.

    - The subject has a known GBA-PD risk-associated variant

    Larson, Danielle NicoleLarson, Danielle Nicole
    • Map it 259 E. Erie St. Lavin Pavillion, Suite 19 100
      Chicago, IL
    NCT05819359 STU00218849
    More Info
    Copy

    The primary objective of this study is to determine whether adjunctive use of Ceregate therapy reduces freezing of gait (FOG) in participants diagnosed with Parkinson's disease.

    Participants diagnosed with Parkinson’s Disease (PD) and previously implanted with a subthalamic nucleus deep brain stimulation (STN-DBS) System.

    Shetty, Neil KantaShetty, Neil Kanta
    NCT05292794 STU00218900
    More Info
    Copy

    The purpose of this study is to evaluate the efficacy of suvecaltamide administered once daily for 17 weeks to improve functional and performance-based impairment due to tremor.

  • Body mass index from 17 to 45 kg/m2 (inclusive) at Screening.
  • Diagnosis of clinically probable or clinically established PD.
  • Participants must be individually optimized for other PD symptoms and on stable PD medications for at least 6 weeks.
  • Shetty, Neil KantaShetty, Neil Kanta
    NCT05642442 STU00218068
    More Info
    Copy

    The purpose of this study is to evaluate the safety and initial efficacy of ECAP-controlled closed-loop spinal cord stimulation (SCS) to treat patients with Parkinson’s Disease symptoms.

    Subject must have moderate/severe freezing of gait and/or tremor considered as a significant source of impairment in the management of their Parkinson's disease.

    Verhagen Metman, LeonardVerhagen Metman, Leonard
    NCT02924129 STU00220312
    More Info
    Copy

    Follow Parkinsons on